Sapanisertib (MLN0128)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Sapanisertib (MLN0128), covering 2026-04-16 to 2026-04-16. Get the full timeline:
Most recent: Clinical Trial Update: Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer [Phase 1]